Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 4/20 | 0.35 |
| ▸ | GABRD | O14764 | 4/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.35 |
| ▸ | GABRE | P78334 | 4/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL15482349 | 0.86 | SLC7A5 (0.43) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL15482351 | 0.86 | SLC7A5 (0.43) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL14764702 | 0.84 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| D-Alanine SCHEMBL614024 | 0.84 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL2784274 | 0.84 | — | — | |
| Alanine SCHEMBL1332110 | 0.84 | — | — | |
| Alanine SCHEMBL254290 | 0.84 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| D-Alanine SCHEMBL2027760 | 0.84 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL452350 | 0.84 | SLC7A5 (0.59) | SLC7A5TP53SLC1A3SLC1A2SLC1A1 | |
| Alanine SCHEMBL31 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042959-A1 | Thrombin-inhibiting peptides | NOESKE-JUNGBLUT CHRISTIANE | 2007-02-22 | — | — | US | disclosed |
| US-20040147442-A1 | For therapy of thromboses, unstable angina, arteriosclerosis, prophylaxis of a re-occlusion of vessels after PTCA/PTA or after thrombolysis for treating a myocardial infarction or for preventing blood clotting in the case of hemodialysis | NOESKE-JUNGBLUT CHRISTIANE | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147442-A1 | For therapy of thromboses, unstable angina, arteriosclerosis, prophylaxis of a re-occlusion of vessels after PTCA/PTA or after thrombolysis for treating a myocardial infarction or for preventing blood clotting in the case of hemodialysis | PLAT, PLAU, PTAFR | SLC7A5 3319/4885TP53 4525/4885SLC1A3 3938/4885 |
| US-20070042959-A1 | Thrombin-inhibiting peptides | SERPINC1, VIP, SERPINE1 | SLC7A5 3878/4885TP53 4091/4885SLC1A3 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.